CASPOFUNGIN

1. Product introduction

　　Caspofungin is the first echinocandin approved for the treatment of invasive fungal infections. In vitro and in vivo tests have demonstrated that Caspofungin has good antimicrobial activity against Candida and Aspergillus, which are important opportunistic infection pathogens. By inhibiting the synthesis of 1,3-β-glucan and causing cell wall rupture, caspofungin has been clinically shown to be effective in the treatment of various types of Candidiasis and Aspergillosis, and also has a good safety profile and patient tolerability. Caspofungin is a synthetic derivative of the cyclic lipopeptide (pneumocandin), a fermentation product of the fungus Glarea lozoyensis, whose molecule is composed of hydrophilic and lipophilic groups: the hydrophilic amino group provides water solubility, while the lipophilic N-acyl group allows its molecule to be inserted into the cell wall of Candida and Aspergillus.

2. Technology parameter

　　Fermentation (Pneumocandin B0) + DSP + synthesis process
　　PB0 Fermentation titre: 1.5g/L; 
　　Fermentation time: 168hrs; 
　　Recovery yield: 35%; 
　　Purity: >97%